A Phase 2 interventional study of Brensocatib and Placebo in Hidradenitis Suppurativa, sponsored by Insmed Incorporated. Terminated at 72 sites in 10 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-06-29.
Sponsored by Insmed Incorporated · Phase 2, Interventional, and Treatment
The primary purpose of the study is to evaluate the effect of brensocatib compared with placebo.
277 studies on the registry are indexed under Hidradenitis Suppurativa; 87 are open to participants now.
This study's enrollment of 214 is above the median of 45 across 195 interventional studies indexed under Hidradenitis Suppurativa.
Browse Hidradenitis Suppurativa studies →Insmed Incorporated is the lead sponsor of 50 studies on the registry; 8 are open to participants now.
Of its 28 completed or terminated interventional studies of FDA-regulated products, 8 (29%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Received systemic (intravenous or orally [PO]) antibiotic therapy within 8 weeks before the Baseline Visit
a. Doxycycline or minocycline up to 100 mg twice daily is permitted provided the dosing regimen being stable for at least 8 weeks before the Baseline Visit and is expected to continue.
Note: Other Inclusion/Exclusion criteria may apply.
Participants will receive brensocatib 10 mg tablet, once daily (QD), orally for 52 weeks.
Drug: Brensocatib
Participants will receive brensocatib 40 mg tablet, QD, orally for 52 weeks.
Drug: Brensocatib
Participants will receive brensocatib-matching placebo tablet, QD, orally for 16 weeks, and then Brensocatib 10 mg tablet, QD, orally for 36 weeks.
Drug: Brensocatib · Drug: Placebo
Participants will receive brensocatib-matching placebo tablet, QD, orally for 16 weeks, and then Brensocatib 40 mg tablet, QD, orally for 36 weeks.
Drug: Brensocatib · Drug: Placebo
Film-coated Oral tablet
Also known as: INS1007
Film-coated Oral tablet
Percent Change From Baseline in Total Abscess and Inflammatory Nodule (AN) Count at Week 16
Time frame: Baseline and Week 16
Percentage of Participants Achieving Hidradenitis Suppurativa Clinical Response 50 (HiSCR50) at Week 16
Time frame: Week 16
Percentage of Participants Achieving HiSCR75 at Week 16
Time frame: Week 16
Percentage of Participants Achieving ≥2-point Decrease From Baseline in Hidradenitis Suppurativa - Investigator's Global Assessment (HS-IGA) at Week 16
Time frame: Week 16
Change From Baseline in Draining Tunnel Count at Week 16
Time frame: Baseline and Week 16
Percentage of Participants Remaining Free from HS Flare by Week 16
Time frame: Week 16
Change From Baseline in International Hidradenitis Suppurativa Severity Score System (IHS4) Score at Week 16
Time frame: Baseline and Week 16
Percentage of Participants Achieving IHS4-55 at Week 16
Time frame: Week 16
Change From Baseline on Dermatology Life Quality Index (DLQI) Global Score at Week 16
Time frame: Baseline and Week 16
Percentage of Participants Achieving Numeric Rating Scale 30 (NRS30) at Week 16 with a Baseline NRS Score ≥3
Time frame: Week 16
Number of Participants who Experienced at Least One Adverse Event (AE)
Time frame: Up to Week 56
Plasma Concentration of Brensocatib
Time frame: Pre-dose and at multiple timepoints post-dose up to Week 56
Plan to share: No
No publications or documents are linked to this record.
This study is terminated, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Insmed Incorporated